Compare Ginkgo Bioworks Holdings Inc (DNA) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Mongodb Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.91 (market cap $763.64M), while Mongodb Inc trades at $372.3 (market cap $29.24B). The key difference: Mongodb Inc is far larger — about 38.3× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is more actively traded (3,204,177 versus 1,304,995). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Mongodb Inc for 45 Days on average.
| DNA | MDB | |
|---|---|---|
Market Cap | $763.64M | $29.24B |
Volume | 3,204,177 | 1,304,995 |
Sector | Health | Technology |
52-Week High | $15.83 | $472.29 |
52-Week Low | $5.48 | $225.95 |
Typical Hold Time | 7 Days | 45 Days |
Enterprise Value | $865.59M | $26.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
MongoDB (MDB) trades at $363.03, up 0.64% today, with a bearish technical signal despite recent positive earnings beats. The company reported strong revenue growth, reaching $2.01 billion in 2025, but remains unprofitable with a net loss of $129.07 million. Recent news highlights AI product launches and a CEO transition, with analysts maintaining a bullish consensus price target of $456.76.
The outlook is mixed: strong revenue growth and AI initiatives offer upside, but high valuation ratios and persistent losses pose risks. Investor sentiment is cautiously optimistic, though technical indicators suggest near-term pressure. Key risks include execution challenges and competitive threats in the database market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
